Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center

home / authors / loretta-j-nastoupil-md-university-of-texas-md-anderson-cancer-center

Articles

Role of Rebiopsy in R/R Follicular Lymphoma

Role of Rebiopsy in R/R Follicular Lymphoma

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;Caron A. Jacobson, MD, Dana-Farber Cancer Institute;Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey;Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center;Krish Patel, MD, Swedish Cancer Institute
March 1st 2021

The rationale for rebiopsying patients who have relapsed/refractory follicular lymphoma and the types of molecular information that can be applied to treatment decisions.

Read More

R/R Follicular Lymphoma: Second-line Treatment Selection

R/R Follicular Lymphoma: Second-line Treatment Selection

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;Caron A. Jacobson, MD, Dana-Farber Cancer Institute;Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey;Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center;Krish Patel, MD, Swedish Cancer Institute
February 22nd 2021

Factors that hematologist-oncologists need to consider when selecting second-line therapy for relapsed follicular lymphoma.

Read More

R/R Follicular Lymphoma: Patient Prognosis

R/R Follicular Lymphoma: Patient Prognosis

Ian Flinn, MD, PhD, Sarah Cannon Research Institute;Caron A. Jacobson, MD, Dana-Farber Cancer Institute;Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey;Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center;Krish Patel, MD, Swedish Cancer Institute
February 22nd 2021

Insight regarding the prognosis for patients with follicular lymphoma who relapse and impact of treatment sequencing on this trajectory.

Read More

<12

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need